AKT1 & SRC Protein Protein Interaction Antibody Pair
- Known as:
- AKT1 & SRC Protein Protein Interaction Antibody Pair
- Catalog number:
- DI0453
- Product Quantity:
- 1 Set
- Category:
- -
- Supplier:
- Abno
- Gene target:
- AKT1 & SRC Protein Interaction Antibody Pair
Related genes to: AKT1 & SRC Protein Protein Interaction Antibody Pair
- Gene:
- AKT1 NIH gene
- Name:
- AKT serine/threonine kinase 1
- Previous symbol:
- -
- Synonyms:
- RAC, PKB, PRKBA, AKT
- Chromosome:
- 14q32.33
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2019-04-23
Related products to: AKT1 & SRC Protein Protein Interaction Antibody Pair
Related articles to: AKT1 & SRC Protein Protein Interaction Antibody Pair
- Evaluate the phytochemical composition of Ginkgo biloba methanolic extract and investigate its anticancer and antibacterial activity, along with exploring its potential molecular mechanism of action through molecular docking analysis. - Source: PubMed
Publication date: 2026/09/01
Ismael Shahad BasilHameed Noor DheyaaAbdulsahib Nawar BahaaAbdalah Mayssaa EYousif Ragheed HussamJabir Majid S - Breast cancer (BC) is the most common cancer among women globally, with Iranian women showing an earlier onset compared to those in Western countries. Genetic variations in the PI3K/AKT/mTOR signaling pathway have been implicated in cancer susceptibility, but limited studies exist on the association of these polymorphisms with BC risk in the Iranian population. This study aimed to investigate the associations of specific polymorphisms in the AKT1, PIK3CA, and mTOR genes with BC susceptibility in an Iranian population. - Source: PubMed
Publication date: 2026/09/01
Mahdizadeh RezaNakhaee AlirezaTaheri MohsenHashemi Seyed MehdiBahari Gholamreza - Oral squamous cell carcinoma (OSCC) remains a significant health burden with limited therapeutic options and high mortality. Sesbania grandiflora, a medicinal plant rich in phytochemicals, has been traditionally used for its medicinal properties and is emerging as a potential anticancer agent. - Source: PubMed
Publication date: 2026/09/01
R Reyana BegamSukumaran GheenaRamasubramaniam Abilasha - Akt is a central serine/threonine kinase in the PI3K/Akt/mTOR pathway that regulates cell survival, growth, and metabolic homeostasis. Although Akt1, Akt2, and Akt3 share high sequence homology, they perform distinct physiological and pathological functions, motivating the development of small-molecule isoform-selective chemical probes. Here, we first applied a molecular hybridization strategy to combine structural features that lead to Akt3-selectivity with the covalent pharmacophore of established covalent-allosteric Akt inhibitors, enabling selective and covalent targeting of Akt3. We then expanded the chemical space of covalent-allosteric Akt inhibitors to investigate how subtle structural differences influence selectivity across all three isoforms. Guided by structure-activity relationships and high-resolution co-crystal structures, systematic modifications of substituent patterns, linker geometry, and scaffold architecture revealed distinct isoform-selectivity profiles. Biochemical target inhibition, cellular target engagement, and covalent-binding studies further characterized these compounds and their selectivity. Collectively, these findings expand the covalent-allosteric Akt inhibitor toolbox, provide insight into the structural determinants governing Akt isoform selectivity, and establish molecular hybridization as a strategy for selective covalent targeting of Akt3. - Source: PubMed
Publication date: 2026/09/29
Pervanidis Kosmas AlexandrosD'Angelo Giovanni DaniloAthanasiadis IoannisJantzen HannahScrima AndreaSchäfer KatharinaQuambusch LenaMüller Matthias PRauh Daniel - Drug resistance is a major challenge in cancer therapy. One promising approach to address this problem is the development of compounds that, when used together with anticancer drugs, can synergistically improve their therapeutic effectiveness. Aiming at sensitizing resistant human breast adenocarcinoma cells (MCF-7/DXR), a set of new urea derivatives (2-9) was prepared by reaction of the natural β-carboline indole alkaloid tryptoline (1) with different aromatic and aliphatic isocyanates. The P-glycoprotein (P-gp) inhibitory potential of compounds 1-9 was assessed by a functional assay. The most significant results were obtained for -[2'-(4″-acetylphenyl)carbamoyl]tryptoline (9), in agreement with molecular docking studies that revealed significant binding affinity to P-gp. Western blot and immunocytochemistry analyses showed that compound 9 led to downregulation of expression, associated with concurrent downregulation of AKT1 signaling. Co-administration of compound 9 with doxorubicin (DOX) significantly reduced fold resistance in MCF-7/DXR cells, almost restoring their sensitivity to levels similar to the parental cell line (from 16.34- to 0.98-fold resistance). Moreover, compound 9 acted synergistically with DOX, markedly increasing its cytotoxicity, associated with a strong increase in apoptosis, reaching approximately 85% apoptotic cells. Molecular analysis showed activation of the intrinsic apoptotic pathway, with increased levels of pro-apoptotic proteins (p53, Bax, caspase-3, and caspase-9) and reduced levels of the anti-apoptotic protein Bcl-2. By increasing ROS production and subsequently inducing oxidative DNA damage, compound 9 markedly amplified DOX-induced cytotoxicity, reinforcing its potential as an effective chemosensitizing agent and warranting further preclinical investigation for potential therapeutic applications. - Source: PubMed
Publication date: 2026/09/18
Barbosa FilipaBalamurugan KarankumarPrasad N RajendraFerreira Maria-José U